Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).

Authors

Mark Jesus Mendoza Magbanua

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Mark Jesus Mendoza Magbanua , Oleksandr Oleksandr Savenkov , Erik Asmus , Karla V. Ballman , Janet H Scott , John Park , Maura N. Dickler , Ann H. Partridge , Lisa A. Carey , Eric P. Winer , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).

First Author: Gabriel N. Hortobagyi

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).

First Author: Antoinette R. Tan

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).

First Author: Esther Anneke Reijm

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).

First Author: Siu W. Lam